Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Recruiting
Observational Study
Non Small Cell Lung Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 70 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
* HER 2 Insertion or Amplification
* First Diagnosis and Treatment
* Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion Criteria:
* Patients received antitumor treatment…
Contacts